Figure 7.

TMOD1 is associated with poor pathological status. TMOD1 expression was analyzed in three pathological subgroups of 25 patients with cervical cancer, from the clinical databases, GEO (GSE2019) and R2 (tumor cervix-Expo MAS5.0). Patients within the stage II group were excluded due to lack of an adequate sample size required for statistical analysis. TMOD1 expression levels for individual samples were analyzed using Affymetrix Human Genome U133 Plus 2.0 Array. *P<0.05. TMOD1, tropomodulin-1; GEO, Gene Expression Omnibus database.